Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2012 / Article

Research Article | Open Access

Volume 2012 |Article ID 313275 | 14 pages | https://doi.org/10.1155/2012/313275

TPEN Induces Apoptosis Independently of Zinc Chelator Activity in a Model of Acute Lymphoblastic Leukemia and Ex Vivo Acute Leukemia Cells through Oxidative Stress and Mitochondria Caspase-3- and AIF-Dependent Pathways

Academic Editor: Felipe Dal-Pizzol
Received25 Sep 2012
Accepted04 Nov 2012
Published23 Dec 2012


Acute lymphoblastic leukemia is still an incurable disease with resistance to therapy developing in the majority of patients. We investigated the effect of TPEN, an intracellular zinc chelator, in Jurkat and in ex vivo acute lymphoblastic leukemia (ALL) cells resistant to chemotherapy. Changes of nuclei morphology, reactive oxygen species generation, presence of hypodiploid cells, phosphatidylserine translocation, mitochondrial membrane depolarization, immunohistochemical identification of cell death signalling molecules, and pharmacological inhibition were assayed to detect the apoptotic cell death pathways. We found that TPEN induces apoptosis in both types of cells by a molecular oxidative stress pathway involving -κB (JNK/c-Jun) loss caspase-3, AIF > chromatin condensation/DNA fragmentation. Interestingly, TPEN induced apoptosis independently of glucose; leukemic cells are therefore devoid of survival capacity by metabolic resistance to treatment. Most importantly, TPEN cytotoxic effect can eventually be regulated by the antioxidant N-acetyl-cysteine and zinc ions. Our data suggest that TPEN can be used as a potential therapeutic prooxidant agent against refractory leukemia. These data contribute to understanding the importance of oxidative stress in the treatment of ALL.

1. Introduction

Leukemia is a malignancy of hematopoietic cell populations responsible of at least 37,520 new cases and 15,200 people deaths in the United States [1]. Although the cause of leukemia is still unknown, several cellular, genetic, and biochemical alterations are the most probable mechanisms of cause [25]. Apoptosis is a controlled and regulated form of programmed cell death defined by specific morphological and biochemical features [68]. Reactivation of the apoptotic cell death appears as a major goal to eliminate cancer cells [9, 10]. Unfortunately, secondary therapy-related leukemia (e.g., acute lymphocytic leukemia, ALL) might emerge following chemotherapy, radiotherapy, and/or terminal differentiation for primary malignancies [1113]. Consequently, leukemia is still an incurable disease with resistance to therapy developing in the majority of patients. Therefore, it is necessary to investigate therapies to either achieve maximal cancer cell death or cell terminal differentiation. Given the complexity of death/differentiation pathways within a cell [8, 1416], placing these pathways in the proper relationship to the drug trigger is challenging. Since metal dysregulation (e.g., zinc) has been shown in patients with leukemia [17, 18] and it is essential cofactor for many proteins and transcription factors [19, 20], it is reasonable to think that the use of chelators might be a potential class of pharmaceutical agents to battle different types of cancer [21, 22]. Therefore, zinc depletion [19, 20] in ALL patients might be a realistic goal.

TPEN (N,N,N,N-Tetrakis(2-pyridylmethyl)-ethylenediamine) is a lipid-soluble zinc metal chelator and has been shown to induce apoptosis in several cancer cells [2327] through caspase family of proteases [25, 2833], transcription factor p53 [28, 33], and X-linked inhibitor of apoptosis protein (XIAP [27]). Yet, the complete molecular mechanism of cell death signaling induced by TPEN in a single cell has not yet fully established. Interestingly, the antioxidant N-acetyl-L-cysteine (NAC) inhibited the cytotoxic effect of TPEN, indicating that oxidative stress (OS) is the likely mediator of Zn-deficiency-related cell death [25]. Remarkably, molecules that generated OS induce a minimal completeness of cell death signaling pathway as a mechanistic explanation of cancer cell demise [34]. We hypothesize that TPEN might induce apoptosis by OS in leukemia cells.

To test this assumption, we sought (i) to determine whether TPEN treatment induces OS through H2O2, and activation of the proapoptotic transcription factors, kinases, and caspase-3 in Jurkat cells, used as a model of human ALL. We also wanted (ii) to determine the role played by the apoptosis-inducing factor (AIF) in TPEN treatment. Glucose appears to be critical pathophysiology resistance against OS in cancer cells [35, 36]. We evaluated therefore whether glucose might alter the survival response to TPEN in Jurkat cells. To validate this in vitro data, ALL cells from one patient resistant to chemotherapy and radiotherapy were challenged with TPEN. ALL cells were similarly evaluated for nuclei morphological changes, loss , p53, and caspase-3 activation or AIF analysis. Understanding the mechanism of OS may provide insight into more effective anticancer therapy.

2. Materials and Methods

3,3′-dihexyloxacarbocyanine iodide ( OC6(3), cat # D-273), ammonium pyrrolidinedithiocarbamate (PDTC, cat. # 548000), and 1,9-pyrazoloanthrone (SP600125, cat # 420119) were acquired from Calbiochem. Propidium Iodide and 7-AAD BD via-probe cell viability was all purchased from BD Bioscience (San Jose, CA). Annexin V-Phycoerythrin (PE) apoptosis detection kit was purchased from BD Pharmingen (San Diego, CA). Dichlorofluorescein diacetate (DCFH2-DA) was obtained from Invitrogen. All other reagents were from Sigma-Aldrich.

2.1. Jurkat T Leukemia Cell Culture

Jurkat clone E6-1 (ATCC Catalog no. TIB-152) were cultured according to supplier’s indications.

2.2. Experiments with Jurkat Leukemia Cell Line
2.2.1. Morphological Assessment of Cell Death by Fluorescence Microscopy and Flow Cytometry Analysis

The cell suspension (1 mL, final volume) was exposed to increasing TPEN (0.1–5 μM) concentrations freshly prepared in RPMI-1640 medium either with glucose (G11, G55; Gibco/Invitrogen) or absence (G0) in the absence or presence different products of interest for 24 h at 37°C. Fluorescent microscopy analysis and quantification of apoptotic morphology was performed according to [37]. The apoptotic indexes were assessed 3 times in independent experiments blind to experimenter. For annexin V/7-AAD flow cytometry analysis, cells were evaluated according to supplier’s protocol (BD Pharmingen, San Diego, CA) with a flow cytometer FACSCanto II, Becton Dickinson (San José, CA). The flow cytometry apoptosis was assessed 3 times in independent experiments.

2.2.2. Determination of DNA Fragmentation by Flow Cytometry

DNA fragmentation was determined by using a hypotonic solution of propidium iodide (PI). Cells entering the sub-G1 phase were used as the marker for apoptosis. Cell suspensions were analyzed in a FACScanto III flow cytometer (Beckton Dickinson). 20,000 events were assessed. Determination of DNA fragmentation was assessed 3 times in independent experiments.

2.2.3. Evaluation of Intracellular Reactive Oxygen Species (ROS)

Superoxide anion radical ( ) was examined for formation of formazan positive cells and quantification was evaluated according to [38]. The assessment was repeated 3 times in independent experiments.

Hydrogen peroxide (H2O2) was determine with 2′,7′-dichlorofluorescein diacetate (5 μM, DCFH2-DA) according to supplier’s protocol using a flow cytometer FACSCanto II, Becton Dickinson (San José, CA). The assessment was repeated 3 times in independent experiments.

2.2.4. Analysis of Mitochondrial Membrane Potential ( ) by Flow Cytometry

Jurkat cell line was treated as described above. Then, cells (1 × 105) were incubated for 20 min at room temperature in the dark with cationic lipophilic DiOC6(3) (10 nM, final concentration) and intercalating agent propidium iodide (PI, 12.5 ng/mL, final concentration) according to standard protocol. Cells were analyzed using a flow cytometer FACSCanto II, Becton Dickinson (San José, CA). The assessment was repeated 3 times in independent experiments.

2.3. Immunocytochemistry Detection of Transcription Factor NF-κB, p53, c-Jun, Caspase-3, and Apoptosis-Inducing Factor (AIF)

The Santa Cruz Biotechnology supplier protocol (goat ABC staining System: cat # sc-2023) was followed for the immunocytochemistry using primary goat polyclonal antibodies NF-κB p65 (C-20)-G (cat # sc-372-G), p53 (FL-393) (cat # sc-6243-G), p-(Ser73)-c-Jun (cat # sc-7981), caspase-3 (cat # sc-22171), and AIF (cat # sc-9417). The cells were immune-stained and diaminobenzidine positive (DAB+) cells were quantified according to [37].

2.4. Protection and Rescue Experiments

The Jurkat cell suspension (1 mL, final volume) was treated with (3 μM) TPEN alone immediately (for protection experiments) or left for 6 h (for rescue experiments). Then after, cells were coincubated with antioxidant and inhibitor reagents at the concentration listed in Table 1 at 37°C for up to 24 h. After this time, cells were evaluated for apoptotic features by either fluorescence microscopy or flow cytometry, as described in previous section. The assessment was repeated 3 times in independent experiments.

Treatment/assay AO/EB/Hoechst (%)AV+/7-AAD−/+ (%)PI−/+/DiOC6(3) (%)

Untreated <1 ± 0
TPEN (3  M)100

PDTC (10 nM)<1 ± 0
PDTC (10 nM) + TPEN (3  M)
SP600125 (1 μM)<1 ± 1
SP600125 (1 μM) + TPEN (3 μM)
PFT (50 nM)<1 ± 0
PFT (50 nM) + TPEN (3 μM)
NSCI (10 μM)<1 ± 0
NSCI (10 μM) + TPEN (3 μM)
ZnSO4 (10 μM)<1 ± 0
ZnSO4 (10 μM) + TPEN (3 μM)
Zn (10 μM)/TPEN (3 μM) complex

NAC (1 mM)<1 ± 0
NAC (1 mM) + TPEN (3 μM)

2.5. Patient Blood Cells Culture Conditions

After obtaining informed consent, peripheral blood was collected from a chemotherapy and radiotherapy resistant ALL cells from a patient (female, 53 years old) diagnosed according to classical morphological, cytogenetic, and immunophenotypical criteria. The Institutional Ethics Committee at University of Antioquia approved this study. Whole blood sample (1 mL) from an ALL patient was incubated with 0, 5, 10, 15, 20 μM TPEN at 37°C for 24 h. A smear of blood (30 μL) was stained with Giemsa and an aliquot (100 μL) was stained with AO/EB/Hoechst dye for nuclei morphological changes analysis. After hemolysis of red blood cells in the remaining sample volume, cells were analyzed for  ΔΨm under identical conditions by flow cytometry. Results represent a mean ± S.D. of two replicas from one experiment. Lymphoblastic cells (LC) purified by Ficoll-Hypaque (Lymphoprep, Bio-Whittaker Products, Verviers, Belgium) were washed thrice with PBS (10 mM sodium phosphate, 160 mM NaCl, pH 7.4) and finally suspended in RPMI-1640 medium (GIBCO laboratories, NY, USA) under standard culture conditions. The LC were plated in 24-wells (1 × 106 cells/mL/well) and treated with similar TPEN concentrations as described above at 37°C for 24 h. LC were used for immunohistochemistry analysis.

2.6. Statistical Analysis

Data are means ± S.D. of three independent experiments. One-way ANOVA analyses with Bonferroni or Games-Howell post-hoc comparison were calculated with SPSS 18 software. A value of and was considered significant.

3. Results

3.1. TPEN Induces Apoptosis in Jurkat Cells in a Concentration- and Time-Dependent Fashion but Independent of Reactive Oxygen Species

As shown in Figure 1, TPEN induces typical morphology of apoptosis (Figure 1(b)) compared to untreated cells (Figure 1(a)) in a concentration-dependent manner (Figure 1(c)). Since we found that 3–5 μM TPEN induces 100% AO/EB/Hoechst positive nuclei staining, we used 3 μM TPEN for further experiments. At this concentration, kinetic analysis shows that TPEN induces production of (Figure 2(a)) in a belt-like shape with a maximum generation at 6 h (Figure 2(c)) and H2O2 (Figure 2(b)) in a time-independent fashion (Figure 2(c)), according to NBT staining and flow cytometry assay, respectively. Additionally, TPEN provokes DNA fragmentation (Figure 3(a)), externalization of phosphatidylserine, (PtdSer, Figure 3(b)), and loss  ΔΨm (Figure 3(c)) in a time-dependent fashion, as determined by flow cytometry assay.

3.2. TPEN Induces Transcription Factors, Caspase-3 Activation, and AIF Nuclei Translocation

Next, we investigated whether TPEN was able to activate transcription factors, JNK kinase, caspase-3 [34], and AIF. As shown in Figure 4, compared to untreated cells (e.g., ~2%, Figure 4(a)), TPEN effectively induced NF-κB (e.g., %, Figure 4(b)), p53 (e.g., %, Figure 4(c)), c-Jun (e.g., %, Figure 4(d)), caspase-3 (e.g., %, Figure 4(e)), and AIF (e.g., %, Figure 4(f)) at 24 h. These observations were further confirmed by incubating Jurkat cells in the presence of pharmacologic inhibitors (Table 1), according to AO/EB/Hoechst staining and flow cytometry technique. Moreover, cells pre-exposed to TPEN for 6 h and then co-incubated with inhibitor compounds were able to rescue Jurkat cells from apoptosis (Table 2).

Treatment/assay AO/EB/Hoechst (%)AV+/7-AAD−/+ (%)PI−/+/DiOC6(3) (%)

Untreated <1 ± 0
TPEN (3 μM)100

PDTC (10 nM)<1 ± 0
PDTC (10 nM) + TPEN (3 μM)
SP600125 (1 μM)<1 ± 1
SP600125 (1 μM) + TPEN (3 μM)
PFT (50 nM)<1 ± 0
PFT (50 nM) + TPEN (3 μM)
NSCI (10 μM)<1 ± 0
NSCI (10 μM) + TPEN (3 μM)
ZnSO4 (10 μM)<1 ± 0
ZnSO4 (10 μM) + TPEN (3 μM)
Zn (10 μM)/TPEN (3 μM) complex

NAC (1 mM)<1 ± 0
NAC (1 mM) + TPEN (3 μM)

3.3. TPEN Induces Apoptosis in Jurkat Cells Independent of Glucose Concentration but Its Toxic Effect Is Diminished by N-Acetyl-Cysteine

As depicted in Figure 5, TPEN induces apoptosis (Figure 5(a)), loss of  ΔΨm (Figure 5(b)), and DNA fragmentation (Figure 5(c)) in Jurkat cells in a glucose-and time-independent manner compared to cells cultured in glucose alone. In contrast, antioxidant compounds such as NAC (1 mM) and zinc ions (10 μM) clearly protects (Table 1) and rescues (Table 2) TPEN-induced apoptosis effect in Jurkat cells. To ascertain that TPEN induces apoptosis meanly via OS, cells were exposed to Zn(SO4)/TPEN complex. No significant difference in nuclei morphology, plasma membrane damage, and loss  ΔΨm were detected in Jurkat cells treated with either the Zn/TPEN complex or treated with Zn plus TPEN (Tables 1 and 2). Furthermore, no significant difference in NBT+ (e.g., %) and DCF+ (e.g., %) percentages were observed between cells treated with Zn/TPEN complex and untreated (Figure 2) or zinc alone (e.g., % NBT+, % DCF+) for 24 h, as indication of reduced and H2O2 production.

3.4. TPEN Induces Apoptosis in ALL Cells via Mitochondria Caspase-Dependent and -Independent Pathways

As shown in Figures 6(b)–6(f), treatment of ALL cells from whole blood sample with TPEN displayed nuclei changes typical of apoptosis compared to untreated cells (Figure 6(a) and inset). Noticeably, these morphologies are comparable to those displayed by Jurkat cells treated with TPEN (Figure 1(b)). Likewise, TPEN induced mitochondrial depolarization (Figure 6(g) versus Figure 6(h)). Interestingly, TPEN induces both phenomena in a concentration dependent fashion (Figure 6(i)). As shown in Figure 7, TPEN significantly induces activation of p53 (Figure 7(b)), caspase-3 (Figure 7(c)), and translocation of AIF to nuclei (Figure 7(d)) compared to cells in absence of zinc chelator (Figure 7(a)) similar to TPEN treated Jurkat cells. Clearly, not only the amount of DAB+ nuclei in ALL cells treated with TPEN was significantly different to DAB+ nuclei in untreated ALL cells, but also the number of AO/EB/Hoechst cells and  ΔΨm markers were significantly different compared to untreated cells (Table 3).

AO/EB/Hoechst (%)PI−/+/DiOC6(3) (%)p53 (%)Caspase-3 (%)AIF (%)

5 ± 29 ± 39 ± 213 ± 216 ± 2
TPEN (5  M)
97 ± 179 ± 274 ± 390 ± 382 ± 3

4. Discussion

In the present investigation, we report for the first time in vitro evidence of a cause and effect mechanism of apoptosis induced by the zinc chelator TPEN in Jurkat cells, and in ALL cells from a leukemic patient. The TPEN-induced apoptosis complies with the model of minimal completeness of cell death signaling induced by OS [34]. Most importantly, we demonstrated that TPEN induced cell death independently of cellular energy requirement (i.e., glucose [39]) in the culture milieu. The model provides therefore a mechanistic explanation of leukemia cell demise. Specifically, we showed that TPEN induces apoptosis primarily via OS. We found that NAC not only significantly protect but also rescue Jurkat cells against TPEN exposure [25]. Moreover, when cells were exposed to Zn/TPEN complex, comparable /H2O2 values to untreated cell were detected; consequently, TPEN-induced apoptosis was significantly reduced. This data implies that zinc disabled TPEN to generate ROS, thereby turning down cell signalling. This observation therefore suggests that TPEN induces apoptosis independently of its metal chelator function. However, the source of TPEN generated is unknown. Whatever the mechanism of generation may be, we have shown that TPEN induces sustained generation of up to six hours of incubation and then slowly declined until complete incubation time (24 h). Overproduction of leads to production of H2O2 through either enzymatic or nonenzymatic reactions. Effectively, TPEN induced a dramatic increase of H2O2 from the first hours up to 12 h (~80%-60%) and then declined to ~30% at 24 h. These H2O2 production values are aberrantly high when compared to base line in untreated cells (~10%). It is accepted that high H2O2 may serves as oxidant signal which might activate critical signalling molecules such as NF-κB [40]. It has been shown that H2O2 indirectly activates the transcription factor NF-κB via several kinases [4145]. Accordingly, TPEN induces activation of NF-κB transcription factor in Jurkat cells showing fragmentation and condensation, typical indication of apoptotic morphology. Pharmacological inhibition of NF-κB with PDTC significantly inhibited TPEN-induced apoptosis. These observations comply with the notion that NF-κB is involved in apoptosis [46, 47] in Jurkat cells exposed to TPEN. In line with this notion, NF-κB transcribes proapoptotic genes such as p53 [48]. TPEN induces p53 activation and translocation to nuclei. TPEN activates p53 not only in Jurkat cells (this work) but also in neuronal cells [28, 33]. It is perhaps not surprising that activated p53 triggers apoptosis by altering mitochondria function [49], suppressing anti-oxidant genes [50] and regulating metabolic genes [51]. These data suggest that p53 acts both as crucial node downstream of diverse stress signals and as a stress sensor. However, p53-induced apoptosis can be stopped and reverse. Specific inhibitor PFT is able to protect and rescue TPEN-induced apoptosis in Jurkat cells. This observation further reinforces the notion that p53 is susceptible to regulation process, thereby potentially directed to specifically destroy malignant cells. P53 has therefore become an excellent candidate to therapeutic approaches against leukaemia cells [5254]. In contrast to Ak and Levine [55], we conclude that both NF-κB and p53 have evolved to respond to OS and that they can function in the same cell at the same time.

TPEN/H2O2 stress provoked loss of  ΔΨm concomitantly with externalization of PtdSer in a time-dependent fashion, as typical marker of apoptosis. However, the flow cytometer values for loss  ΔΨm and PtdSer were significantly different. This observation suggests that either drop  ΔΨm occurs previous to externalization of PtdSer or Annexin V assay unsuccessfully label all apoptotic cells [56]. In accordance with others [25, 28, 3033], we found caspase-3 activation in treated cells. The participation of caspase-3 in TPEN toxicity was confirmed by using NSCI inhibitor, which not only protects but also rescues cells from TPEN toxicity. Caspase-3 activation therefore constitutes a critical protease and a marker of cell death induced by OS. We report for the first time that TPEN provokes AIF to translocate to the nucleus and induces chromatin condensation. In contrast to others [57], AIF is primarily involved in apoptosis in Jurkat cells exposed to TPEN, at least under the present experimental conditions. In support of this view, Stambolsky et al. [58] have shown that p53 regulates expression of AIF. We conclude that depending on the cell type and stress stimuli, AIF might be involved in apoptosis or necrosis [57, 59]. It is concluded that TPEN induces apoptosis in Jurkat cells mainly mitochondrial-mediated pathway [60] by two complimentary but independent cell death subroutes: AIF- and caspase-3 dependent mechanism. However, we found that the proportion of nuclei in stage II detected by fluorescence microscopy was higher than the proportion of nuclei in stage I. One possible explanation is that TPEN chelates zinc from caspase-3, increasing its catalytic activity [32] and thereby overpassing the mitochondrial caspase activation process. Furthermore, TPEN also destroy XIAP, a natural caspase-3 inhibitor [27]. It is therefore not surprising that zinc, being a potent inhibitor of caspase-3 [61], protects and rescues Jurkat cells from TPEN toxic effects. Therefore, AIF and caspase 3 should be used as regular markers of cell death. Additionally, TPEN induces apoptosis via activation of c-Jun and JNK kinase and their activation might be mediated by H2O2 [62]. It has been reported that JNK phosphorylated p53 [63]. In view of the present data and those reported by Yin et al. [64] comply with the notion that NF-κB, JNK and p53 pathways are involved in OS in HepG2 cells and Jurkat cells (this work).

We found that TPEN-induced nuclei fragmentation morphology and loss  ΔΨm in a concentration-dependent manner in whole blood cells from ALL patient. Treatment of isolated ALL cells with (5μM) TPEN displayed p53, caspase-3, and AIF DAB+ compared to untreated cells. These data suggest that TPEN induces apoptosis in ALL leukemic cells by a similar mechanism as the one induced by TPEN in Jurkat cells (Figure 8). However, we noticed that almost fivefold concentration of TPEN was necessary on whole blood ALL cells to reach a comparable value of apoptosis in Jurkat cells treated with TPEN. Since TPEN was able to fully induce apoptosis in ALL via activation of cell death signaling mechanism, it is concluded that the resistance of the ALL cells to chemotherapy is unrelated to malfunction of the cells’ death machinery elements, at least, in the death markers assessed in this work, but most probably by other genetic alterations [65, 66]. It is therefore proposed that TPEN might be explored as potential therapeutic agent molecule against ALL leukemia.

Conflict of Interests

The authors report no conflict of interests.


This work was supported by Colciencias grants nos.1115-408-20525 to C. Velez-Pardo and M. Jimenez-Del-Rio. M. Mendivil-Perez is an associated researcher funded by Colciencias Contract no. 8790-2514-2010 and funded from a Young Research Program Award by Colciencias contract no. 8790-016-2011. The authors thank Dr. F. Cuellar, MD (Hematologist) from Leon XIII Clinic and the ALL patient for blood cell sample donation. They thank Catalina Burbano-Arciniegas from the Flow Cytometry Unit, GICIG-SIU-UdeA for technical assistance.


  1. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics 2012,” A Cancer Journal for Clinicians, vol. 62, pp. 10–29, 2012. View at: Google Scholar
  2. G. Pasternak, A. Hochhaus, B. Schultheis, and R. Hehlmann, “Chronic myelogenous leukemia: molecular and cellular aspects,” Journal of Cancer Research and Clinical Oncology, vol. 124, no. 12, pp. 643–660, 1998. View at: Publisher Site | Google Scholar
  3. C. H. Pui, M. V. Relling, and J. R. Downing, “Mechanisms of disease: acute lymphoblastic leukemia,” The New England Journal of Medicine, vol. 350, no. 15, pp. 1535–1548, 2004. View at: Publisher Site | Google Scholar
  4. D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,” Cell, vol. 100, no. 1, pp. 57–70, 2000. View at: Google Scholar
  5. D. A. Tennant, R. V. Durán, H. Boulahbel, and E. Gottlieb, “Metabolic transformation in cancer,” Carcinogenesis, vol. 30, no. 8, pp. 1269–1280, 2009. View at: Publisher Site | Google Scholar
  6. J. F. R. Kerr, G. C. Gobé, C. M. Winterford, and B. V. Harmon, “Chapter 1 anatomical methods in cell death,” Methods in Cell Biology C, vol. 46, pp. 1–27, 1995. View at: Publisher Site | Google Scholar
  7. G. Kroemer, L. Galluzzi, P. Vandenabeele et al., “Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009,” Cell Death and Differentiation, vol. 16, no. 1, pp. 3–11, 2009. View at: Publisher Site | Google Scholar
  8. L. Galluzzi, I. Vitale, J. M. Abrams et al., “Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012,” Cell Death and Differentiation, vol. 19, pp. 107–120, 2011. View at: Publisher Site | Google Scholar
  9. D. Nowak, D. Stewart, and H. P. Koeffler, “Differentiation therapy of leukemia: 3 decades of development,” Blood, vol. 113, no. 16, pp. 3655–3665, 2009. View at: Publisher Site | Google Scholar
  10. G. L. Kelly and A. Strasser, “The essential role of evasion from cell death in cancer,” Advances in Cancer Research, vol. 111, pp. 39–96, 2011. View at: Publisher Site | Google Scholar
  11. W. Chen, E. Wang, Y. Lu, K. K. Gaal, and Q. Huang, “Therapy-related acute lymphoblastic leukemia without 11q23 abnormality: report of six cases and a literature review,” American Journal of Clinical Pathology, vol. 133, no. 1, pp. 75–82, 2010. View at: Publisher Site | Google Scholar
  12. T. Szotkowski, P. Rohon, L. Zapletalova, K. Sicova, J. Hubacek, and K. Indrak, “Secondary acute myeloid leukemia—a single center experience,” Neoplasma, vol. 57, no. 2, pp. 170–178, 2010. View at: Publisher Site | Google Scholar
  13. C. Kelaidi, L. Adès, and P. Fenaux, “Treatment of acute promyelocytic leukemia with high white cell blood counts,” Mediterranean Journal of Hematology and Infectious Diseases, vol. 3, Article ID e2011038, 2011. View at: Google Scholar
  14. J. C. Reed, “Warner-Lambert/Parke Davis award lecture: mechanisms of apoptosis,” American Journal of Pathology, vol. 157, no. 5, pp. 1415–1430, 2000. View at: Google Scholar
  15. The KEGG (Kyoto Encyclopedia of Genes and Genomes) PATHWAY Database, (Apoptosis), http://www.genome.jp/kegg/pathway/hsa/hsa04210.html.
  16. T. P. Dang, “Notch apoptosis and cancer,” Advances in Experimental Medicine and Biology, vol. 727, pp. 199–209, 2012. View at: Google Scholar
  17. X. L. Zuo, J. M. Chen, X. Zhou, X. Z. Li, and G. Y. Mei, “Levels of selenium, zinc, copper, and antioxidant enzyme activity in patients with leukemia,” Biological Trace Element Research, vol. 114, no. 1–3, pp. 41–53, 2006. View at: Google Scholar
  18. R. Ciarcia, D. D'Angelo, C. Pacilio et al., “Dysregulated calcium homeostasis and oxidative stress in chronic myeloid leukemia (CML) cells,” Journal of Cellular Physiology, vol. 224, no. 2, pp. 443–453, 2010. View at: Publisher Site | Google Scholar
  19. B. L. Vallee and K. H. Falchuk, “The biochemical basis of zinc physiology,” Physiological Reviews, vol. 73, no. 1, pp. 79–118, 1993. View at: Google Scholar
  20. L. M. Plum, L. Rink, and H. Hajo, “The essential toxin: impact of zinc on human health,” International Journal of Environmental Research and Public Health, vol. 7, no. 4, pp. 1342–1365, 2010. View at: Publisher Site | Google Scholar
  21. R. Zhao, R. P. Planalp, R. Ma et al., “Role of zinc and iron chelation in apoptosis mediated by tachpyridine, an anti-cancer iron chelator,” Biochemical Pharmacology, vol. 67, no. 9, pp. 1677–1688, 2004. View at: Publisher Site | Google Scholar
  22. G. Khan and S. Merajver, “Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm,” Expert Opinion on Investigational Drugs, vol. 18, no. 4, pp. 541–548, 2009. View at: Publisher Site | Google Scholar
  23. M. Adler, H. Shafer, T. Hamilton, and J. P. Petrali, “Cytotoxic actions of the heavy metal chelator TPEN on NG108-15 neuroblastoma-glioma cells,” NeuroToxicology, vol. 20, no. 4, pp. 571–582, 1999. View at: Google Scholar
  24. M. Donadelli, E. D. Pozza, C. Costanzo, M. T. Scupoli, A. Scarpa, and M. Palmieri, “Zinc depletion efficiently inhibits pancreatic cancer cell growth by increasing the ratio of antiproliferative/proliferative genes,” Journal of Cellular Biochemistry, vol. 104, no. 1, pp. 202–212, 2008. View at: Publisher Site | Google Scholar
  25. M. Hashemi, S. Ghavami, M. Eshraghi, E. P. Booy, and M. Los, “Cytotoxic effects of intra and extracellular zinc chelation on human breast cancer cells,” European Journal of Pharmacology, vol. 557, no. 1, pp. 9–19, 2007. View at: Publisher Site | Google Scholar
  26. S. Jiang, B. Zhivotovsky, D. H. Burgess, A. Gahm, S. C. Chow, and S. Orrenius, “The role of proteolysis in T cell apoptosis triggered by chelation of intracellular Zn2+,” Cell Death and Differentiation, vol. 4, no. 1, pp. 39–50, 1997. View at: Google Scholar
  27. P. Makhov, K. Golovine, R. G. Uzzo et al., “Zinc chelation induces rapid depletion of the X-linked inhibitor of apoptosis and sensitizes prostate cancer cells to TRAIL-mediated apoptosis,” Cell Death and Differentiation, vol. 15, no. 11, pp. 1745–1751, 2008. View at: Publisher Site | Google Scholar
  28. R. S. Corniola, N. M. Tassabehji, J. Hare, G. Sharma, and C. W. Levenson, “Zinc deficiency impairs neuronal precursor cell proliferation and induces apoptosis via p53-mediated mechanisms,” Brain Research C, vol. 1237, pp. 52–61, 2008. View at: Publisher Site | Google Scholar
  29. V. M. Kolenko, R. G. Uzzo, N. Dulin, E. Hauzman, R. Bukowski, and J. H. Finke, “Mechanism of apoptosis induced by zinc deficiency in peripheral blood T lymphocytes,” Apoptosis, vol. 6, no. 6, pp. 419–429, 2001. View at: Publisher Site | Google Scholar
  30. J. M. Lee, Y. J. Kim, H. Ra et al., “The involvement of caspase-11 in TPEN-induced apoptosis,” FEBS Letters, vol. 582, no. 13, pp. 1871–1876, 2008. View at: Publisher Site | Google Scholar
  31. J. J. López, P. C. Redondo, G. M. Salido, J. A. Pariente, and J. A. Rosado, “N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine induces apoptosis through the activation of caspases-3 and -8 in human platelets. A role for endoplasmic reticulum stress,” Journal of Thrombosis and Haemostasis, vol. 7, no. 6, pp. 992–999, 2009. View at: Publisher Site | Google Scholar
  32. M. Marini, F. Frabetti, S. Canaider, L. Dini, E. Falcieri, and G. G. Poirier, “Modulation of caspase-3 activity by zinc ions and by the cell redox state,” Experimental Cell Research, vol. 266, no. 2, pp. 323–332, 2001. View at: Publisher Site | Google Scholar
  33. H. Ra, H. L. Kim, H. W. Lee, and Y. H. Kim, “Essential role of p53 in TPEN-induced neuronal apoptosis,” FEBS Letters, vol. 583, no. 9, pp. 1516–1520, 2009. View at: Publisher Site | Google Scholar
  34. M. Jimenez-Del-Rio and C. Velez-Pardo, “The bad the good and the ugly about oxidative stress,” Oxidative Medicine and Cellular Longevity, vol. 2012, 13 pages, 2012. View at: Google Scholar
  35. C. Le Goffe, G. Vallette, L. Charrier et al., “Metabolic control of resistance of human epithelial cells to H2O2 and NO stresses,” Biochemical Journal, vol. 364, no. 2, pp. 349–359, 2002. View at: Publisher Site | Google Scholar
  36. R. B. Hamanaka and N. S. Chandel, “Targeting glucose metabolism for cancer therapy,” The Journal of Experimental Medicine, vol. 209, pp. 211–215, 2012. View at: Google Scholar
  37. A. R. Bonilla-Porras, M. Jimenez-Del-Rio, and C. Velez-Pardo, “Vitamin K3 and vitamin C alone or in combination induced apoptosis in leukemia cells by a similar oxidative stress signalling mechanism,” Cancer Cell International, vol. 11, article 19, 2011. View at: Publisher Site | Google Scholar
  38. M. Melinn and H. McLaughlin, “Nitroblue tetrazolium reduction in lymphocytes,” Journal of Leukocyte Biology, vol. 41, no. 4, pp. 325–329, 1987. View at: Google Scholar
  39. A. Annibaldi and C. Widmann, “Glucose metabolism in cancer cells,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 13, no. 4, pp. 466–470, 2010. View at: Publisher Site | Google Scholar
  40. R. Brigelius-Flohé and L. Flohé, “Basic principles and emerging concepts in the redox control of transcription factors,” Antioxidants and Redox Signaling, vol. 15, pp. 2335–2381, 2011. View at: Google Scholar
  41. G. Gloire, E. Charlier, S. Rahmouni et al., “Restoration of SHIP-1 activity in human leukemic cells modifies NF-κB activation pathway and cellular survival upon oxidative stress,” Oncogene, vol. 25, no. 40, pp. 5485–5494, 2006. View at: Publisher Site | Google Scholar
  42. H. Ichijo, E. Nishida, K. Irie et al., “Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways,” Science, vol. 275, no. 5296, pp. 90–94, 1997. View at: Publisher Site | Google Scholar
  43. F. S. Lee, J. Hagler, Z. J. Chen, and T. Maniatis, “Activation of the IκBα kinase complex by MEKK1, a kinase of the JNK pathway,” Cell, vol. 88, no. 2, pp. 213–222, 1997. View at: Publisher Site | Google Scholar
  44. S. Schoonbroodt, V. Ferreira, M. Best-Belpomme et al., “Crucial role of the amino-terminal tyrosine residue 42 and the carboxylterminal PEST domain of IκBα in NF-κB activation by an oxidative stress,” Journal of Immunology, vol. 164, no. 8, pp. 4292–4300, 2000. View at: Google Scholar
  45. Y. Takada, A. Mukhopadhyay, G. C. Kundu, G. H. Mahabeleshwar, S. Singh, and B. B. Aggarwal, “Hydrogen peroxide activates NF-κB through tyrosine phosphorylation of IκBα and serine phosphorylation of p65. Evidence for the involvement of IκBα kinase and Syk protein-tyrosine kinase,” Journal of Biological Chemistry, vol. 278, no. 26, pp. 24233–24241, 2003. View at: Publisher Site | Google Scholar
  46. Y. Fan, J. Dutta, N. Gupta, G. Fan, and C. Gélinas, “Regulation of programmed cell death by NF-κB and its role in tumorigenesis and therapy,” Advances in Experimental Medicine and Biology, vol. 615, pp. 223–250, 2008. View at: Publisher Site | Google Scholar
  47. S. K. Radhakrishnan and S. Kamalakaran, “Pro-apoptotic role of NF-κB: implications for cancer therapy,” Biochimica et Biophysica Acta, vol. 1766, no. 1, pp. 53–62, 2006. View at: Publisher Site | Google Scholar
  48. H. Wu and G. Lozano, “NF-κB activation of p53. A potential mechanism for suppressing cell growth in response to stress,” Journal of Biological Chemistry, vol. 269, no. 31, pp. 20067–20074, 1994. View at: Google Scholar
  49. A. V. Vaseva and U. M. Moll, “The mitochondrial p53 pathway,” Biochimica et Biophysica Acta, vol. 1787, no. 5, pp. 414–420, 2009. View at: Publisher Site | Google Scholar
  50. I. A. Olovnikov, J. E. Kravchenko, and P. M. Chumakov, “Homeostatic functions of the p53 tumor suppressor: regulation of energy metabolism and antioxidant defense,” Seminars in Cancer Biology, vol. 19, no. 1, pp. 32–41, 2009. View at: Publisher Site | Google Scholar
  51. X. D. Zhang, Z. H. Qin, and J. Wang, “The role of p53 in cell metabolism,” Acta Pharmacologica Sinica, vol. 31, no. 9, pp. 1208–1212, 2010. View at: Publisher Site | Google Scholar
  52. E. McCormack, I. Haaland, G. Venas et al., “Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia,” Leukemia, vol. 26, pp. 910–907, 2012. View at: Google Scholar
  53. M. N. Saha, J. Micallef, L. Qiu, and H. Chang, “Pharmacological activation of the p53 pathway in haematological malignancies,” Journal of Clinical Pathology, vol. 63, no. 3, pp. 204–209, 2010. View at: Publisher Site | Google Scholar
  54. J. W. Tyner, A. M. Jemal, M. Thayer, B. J. Druker, and B. H. Chang, “Targeting surviving and p53 in pediatric acute lymphoblastic leukemia,” Leukemia, vol. 26, pp. 623–632, 2012. View at: Google Scholar
  55. P. Ak and A. J. Levine, “p53 and NF-κB: different strategies for responding to stress lead to a functional antagonism,” The FASEB Journal, vol. 24, no. 10, pp. 3643–3652, 2010. View at: Publisher Site | Google Scholar
  56. M. C. Willingham, “Cytochemical methods for the detection of apoptosis,” Journal of Histochemistry and Cytochemistry, vol. 47, no. 9, pp. 1101–1110, 1999. View at: Google Scholar
  57. H. Boujrad, O. Gubkina, N. Robert, S. Krantic, and S. A. Susin, “AIF-mediated programmed necrosis: a highly regulated way to die,” Cell Cycle, vol. 6, no. 21, pp. 2612–2619, 2007. View at: Google Scholar
  58. P. Stambolsky, L. Weisz, I. Shats et al., “Regulation of AIF expression by p53,” Cell Death and Differentiation, vol. 13, no. 12, pp. 2140–2149, 2006. View at: Publisher Site | Google Scholar
  59. S. Perez-Alvarez, V. Iglesias-Guimarais, M. E. Solesio et al., “Methadone induces CAD degradation and AIF-mediated necrotic-like cell death in neuroblastoma cells,” Pharmacological Research, vol. 63, no. 4, pp. 352–360, 2011. View at: Publisher Site | Google Scholar
  60. B. Guo, M. Yang, D. Liang, L. Yang, J. Cao, and L. Zhang, “Cell apoptosis induced by zinc deficiency in osteoblastic MC3T3-E1 cells via a mitochondrial-mediated pathway,” Molecular and Cellular Biochemistry, vol. 361, pp. 209–216, 2012. View at: Google Scholar
  61. D. K. Perry, M. J. Smyth, H. R. Stennicke et al., “Zinc is a potent inhibitor of the apoptotic protease, caspase-3: a novel target for zinc in the inhibition of apoptosis,” Journal of Biological Chemistry, vol. 272, no. 30, pp. 18530–18533, 1997. View at: Publisher Site | Google Scholar
  62. Y. O. Son, Y. S. Jang, X. Shi, and J. C. Lee, “Activation of JNK and c-Jun is involved in glucose oxidase-mediated cell death of human lymphoma cells,” Molecules and Cells, vol. 28, no. 6, pp. 545–551, 2009. View at: Publisher Site | Google Scholar
  63. T. Buschmann, O. Potapova, A. Bar-Shira et al., “Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress,” Molecular and Cellular Biology, vol. 21, no. 8, pp. 2743–2754, 2001. View at: Publisher Site | Google Scholar
  64. Y. Yin, W. Chen, C. Tang et al., “NF-κB JNK and p53 pathways are involved in tubeimoside-1-induced apoptosis in HepG2 cells with oxidative stress and G2/M cell cycle arrest,” Food and Chemical Toxicology, vol. 49, pp. 3046–3054, 2011. View at: Google Scholar
  65. C. Palmi, E. Vendramini, D. Silvestri et al., “Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia,” Leukemia, vol. 26, no. 10, pp. 2245–2253. View at: Google Scholar
  66. M. Schrappe, S. P. Hunger, C. H. Pui et al., “Outcomes after induction failure in childhood acute lymphoblastic leukemia,” The New England Journal of Medicine, vol. 366, pp. 1371–1381, 2012. View at: Google Scholar

Copyright © 2012 Miguel Mendivil-Perez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

2570 Views | 1131 Downloads | 28 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.